Michael Harrison

@MRHarrisonMD

GU medical oncologist, Associate Professor of Medicine, and clinical researcher at Duke Cancer Institute. All tweets and views my own.

Durham, NC Joined May 2015

528 Following 727 Followers 500 Posts

Latest posts 5

Michael Harrison @MRHarrisonMD Feb 28

Nice one table summary by @brian_rini putting today’s LITESPARK-011 results (presented just now @GU26) in context. @Uromigos @DukeCancer

Brian Rini, MD @brian_rini Feb 28

Combination therapy is emerging as a standard in refractory RCC. Combos increase tumor shrinkage endpoints. TKI provides early disease control. CRs are possible but is cure? Toxicity consideration is critical in this setting. Biomarkers to guide choice of drug(s) are needed

View quoted post on X

Michael Harrison @MRHarrisonMD Feb 26

@Daniel_J_George did an awesome job putting the PROs from CAPItello-281 in clinical context, especially in relation to AEs and early vs late changes @GU26

Michael Harrison @MRHarrisonMD Feb 26

Very clear and cogent explanation of PCWG4 guidelines (just published!) by my friend and colleague @AarmstrongDuke @GU26

Michael Harrison @MRHarrisonMD Feb 26

General session on Tx Selection, Response Assessment and Monitoring in Advanced Prostate Cancer @GU26 starting now! I wore my Duke socks.

Michael Harrison @MRHarrisonMD Feb 26

It’s almost showtime! Oral Abstract Session A: Prostate Cancer is about to kickoff #GU26